Nelistotug

{
  "id": "MLC-T-ONC-015465",
  "term": "Nelistotug",
  "field": "Oncology and biomedicine",
  "definition": "A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor CD96 (Tactile; T-cell activation increased late expression), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, nelistotug targets, binds to and inhibits CD96 expressed primarily on T cells and natural killer (NK) cells, thereby preventing its downstream signaling pathways. This may abrogate CD96-mediated inhibition of T-cell and NK cell effector function and may restore immune function and anti-tumor immune responses through the activation of T cells and NKs. This may kill and inhibit growth of tumor cells. CD96, a type I transmembrane glycoprotein of the immunoglobulin superfamily and immunological checkpoint for CD8+ T cells and NK cells, negatively regulates T-cell and NK cell activation and is overexpressed in a variety of cancer settings.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/nelistotug/"
}